식약처는 라니티딘 복용 환자 중 6주 이하의 단기복용 환자의 비율이 높은 것으로 추산했다.
The Ministry of Food and Drug Safety estimated that among patients administering ranitidine, the proportion of patients administering for short-term use up to six weeks was high.